Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6609-6620

  Sawant, Anandi ^a   Schafer, Cara C ^b   Jin, Tong Huan ^b   Zmijewski, Jaroslaw ^b   Tse, Hubert M ^c   Roth, Justin ^d   Sun, Zhihuan ^b   Siegal, Gene P ^a   Thannickal, Victor J ^b   Grant, Stefan C ^b   Ponnazhagan, Selvarangan ^a   Deshane, Jessy S ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GEMCITABINE; MANGANESE MESOTETRAKIS(DI N DIETHYLIMIDAZOLE)PORPHYRIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL METABOLISM; CELL RENEWAL; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RECHALLENGE; DRUG TARGETING; EFFECTOR CELL; ERADICATION THERAPY; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INHIBITION KINETICS; LUNG CANCER; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MYELOID CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84888380898     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0987     Document Type: Article

References (42)

1. Society AC. Cancer facts and figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review. Bethesda, MD: U.S. National Institutes of Health, National Cancer Institute; 1973-2008.
3. William WN Jr, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011;8:611-9.
4. Lawless MW, O'Byrne KJ, Gray SG. Targeting oxidative stress in cancer. Expert Opin Ther Targets 2010;14:1225-45.
5. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, et al. A dual role for the immune response in a mouse model of inflammationassociated lung cancer. J Clin Invest 2011;121:2436-46.
6. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012;1:271-8.
7. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
8. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59:1593-600.
9. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
10. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012;4:291-304.
11. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011;71:5101- 10.
12. Deshane J, Zmijewski JW, Luther R, Gaggar A, Deshane R, Lai JF, et al. Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung infl ammation and airway hyperresponsiveness. Mucosal Immunol 2011;4:503-18.
13. Chun SH, Lee JE, Park MH, Kang JH, Kim YK, Wang YP, et al. Gemcitabine plus platinum combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a retrospective analysis. Cancer Res Treat 2011;43:217-24.
14. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21. (Pubitemid 41339014)
15. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009;9:900-9.
16. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, et al. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids 2012;42:95-113.
17. Batinic-Haberle I, Reboucas JS, Spasojevic I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 2010;13:877-918.
18. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72: 2162-71.
19. Kennedy BC, Shimato S, Anderson RC, Bruce JN. Defining the mechanisms of CD8 T-cell tumor tolerance. Immunotherapy 2011;3: 23-26.
20. Apetoh L, Vegran F, Ladoire S, Ghiringhelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 2011;11: 365-72.
21. Yu XZ, Anasetti C. Memory stem cells sustain disease. Nat Med 2005; 11:1282-3. (Pubitemid 41752904)
22. Mehrotra S, Mougiakakos D, Johansson CC, Voelkel-Johnson C, Kiessling R. Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res 2009;102:197-227.
23. Takahashi A, Hanson MG, Norell HR, Havelka AM, Kono K, Malmberg KJ, et al. Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol 2005;174:6080-7. (Pubitemid 40663796)
24. Wang Y, Ma X, Yan S, Shen S, Zhu H, Gu Y, et al. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res 2009;69:7302-10.
25. Xie Y, Kole S, Precht P, Pazin MJ, Bernier M. S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling. Endocrinology 2009;150:1122-31.
26. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011;35:806-18.
27. Peden DB. The role of oxidative stress and innate immunity in O(3) and endotoxin-induced human allergic airway disease. Immunol Rev 2011; 242:91-105.
28. Nakamura K, Yube K, Miyatake A, Cambier JC, Hirashima M. Involvement of CD4 D3-D4 membrane proximal extracellular domain for the inhibitory effect of oxidative stress on activation-induced CD4 downregulation and its possible role for T cell activation. Mol Immunol 2003; 39:909-21. (Pubitemid 36419603)
29. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63. (Pubitemid 38680440)
30. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-12. (Pubitemid 46718405)
31. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011;121:4015-29.
32. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013;62:383-91.
33. Sim SH, Ahn YO, Yoon J, Kim TM, Lee SH, Kim DW, et al. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non- small cell lung cancer. Cancer Sci 2012;103:155-60.
34. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108.
35. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-54. (Pubitemid 41113195)
36. Shimizu K, Rajapakse N, Horiguchi T, Payne RM, Busija DW. Protective effect of a new nonpeptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. Brain Res 2003;963:8-14. (Pubitemid 36126282)
37. Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling X, et al. Oxidative stress in type 1 diabetes. Ann N Y Acad Sci 2003;1005: 43-54. (Pubitemid 38507733)
38. Kaul DK, Liu XD, Zhang X, Ma L, Hsia CJ, Nagel RL. Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants. Am J Physiol Heart Circ Physiol 2006;291:H167-175.
39. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, Feng QF, Kang SK, Spasojevic I, et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 2002; 33:857-63. (Pubitemid 35232320)
40. Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z, et al. A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 2005;63:545-52. (Pubitemid 41317173)
41. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, et al. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res 2007;27:3101-9.
42. van der Windt GJ, Pearce EL Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev 2012;249:27-42.